Discussion
Treatment with Soliris (eculizumab) provides comparable and sustained improvements in daily living and muscle strength in Japanese and Caucasian patients with treatment-resistant generalized myasthenia gravis (gMG), according to one-year data of REGAIN’s extension study. Efficacy and safety were maintained up to 52 weeks in both patient groups and were consistent…